Clofazimine has delayed antimicrobial activity against Mycobacterium tuberculosis both in vitro and in vivo

Nicole C. Ammerman, Rosemary V. Swanson, Asa Tapley, Chivonne Moodley, Bongani Ngcobo, John Adamson, Afton Dorasamy, Sashen Moodley, Zinhle Mgaga, Linda A. Bester, Sanil D. Singh, Deepak V. Almeida, Jacques H. Grosset

Research output: Contribution to journalArticlepeer-review

Abstract

Objectives: The anti-leprosy drug clofazimine has been shown to have antimicrobial activity against Mycobacterium tuberculosis and has been associated with treatment-shortening activity in both clinical and preclinical studies of TB chemotherapy. However, a reported lack of early bactericidal activity (EBA) in TB patients has raised questions regarding the usefulness of clofazimine as an anti-TB drug. Our objective was to systematically evaluate the EBA of clofazimine in vitro and in vivo to provide insight into how and when this drug exerts its antimicrobial activity against M. tuberculosis. Methods:We evaluated the 14 day EBA of clofazimine (i) in vitro at concentrations ranging from 4 times below to 4 times above the MIC for M. tuberculosis and (ii) in vivo in infected BALB/c mice at doses ranging from 1.5 to 100 mg/kg/day, and serum clofazimine levels were measured. In both experiments, isoniazid was used as the positive control. Results: In vitro, clofazimine, at any concentration tested, did not exhibit bactericidal activity during the first week of exposure; however, in the second week, it exhibited concentration-dependent antimicrobial activity. In vivo, clofazimine, at any dose administered, did not exhibit bactericidal activity during the first week, and limited antimicrobial activity was observed during the second week of administration. While serum clofazimine levels were clearly dose dependent, the antimicrobial activity was not significantly related to the dose administered. Conclusions: Our data suggest that clofazimine's delayed antimicrobial activity may be due more to its mechanism of action rather than to host-related factors.

Original languageEnglish (US)
Pages (from-to)455-461
Number of pages7
JournalJournal of Antimicrobial Chemotherapy
Volume72
Issue number2
DOIs
StatePublished - Feb 2017

ASJC Scopus subject areas

  • Pharmacology
  • Microbiology (medical)
  • Infectious Diseases
  • Pharmacology (medical)

Fingerprint Dive into the research topics of 'Clofazimine has delayed antimicrobial activity against Mycobacterium tuberculosis both in vitro and in vivo'. Together they form a unique fingerprint.

Cite this